S100A9 and cancer: Studies had revealed that tumour cells could secrete S100A9 to recruit myeloid‐derived suppressor cells (MDSCs), thereby promoting cancer growth and forming a special pre‐metastatic immunosuppressive niche.53 Liu et al discovered that LINC00852 targeted S100A9 to activate the MAPK signalling pathway, thereby contributing to the formation of a metastatic microenvironment, enhancing NSCLC cell migration and invasion, and eventually facilitating spinal metastasis.54